

Early Breast Cancer Portfolio

Updated 05/01/2024

Breast Ca type	Screening / During Diagnosis	Neo Adj / Window of Opportunity/ Pre Surgery	Surgical	Adjuvant	Loco- regional reccurance	Follow-up
Mutation Specific	EMBRACE	Partner/Partnering (BRCA+, Her2-) – Recruitment on				Olympia
ER+ Her2-				Optima PRIMETIME [AZ Cambria-1] [AZ Cambria-2]		Artemis PRIMETIME Neo-RT
Her2+				Astefania-HER2Radical		Persephone
TNBC		Partnering – recruitment on hold [IMpALA]		TROPION-Breast-3 SIV complete		Partner
Any	BRAID MyPeBs EMBED1&2	PBCP MIPA Narnia Mission Breast TRICKS [Neo-Taxis]	PBCP ATNEC Small	PARABLE	KORTUC	Quartus Fast Forward Import High Import Low POSNOG Add Aspirin
DCIS						

Closed to recruitment, pts in follow up
[Trials in set up]

Early Br Ca Trial information and links

Trial	Description
Add Aspirin	Add-Aspirin: A Trial Assessing the Effects of Aspirin on Disease Recurrence and Survival After Primary Therapy in Common Non Metastatic Solid Tumours - Full Text View - ClinicalTrials.gov
Astefania	A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy - Full Text View - ClinicalTrials.gov
ATNEC	Axillary Management in Breast Cancer Patients With Needle Biopsy Proven Nodal Metastases After Neoadjuvant Chemotherapy - Full Text View - ClinicalTrials.gov
AZ Cambria 1	Study Details A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy ClinicalTrials.gov
AZ Cambria 2	An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) - Full Text View - ClinicalTrials.gov
Breast TRICKS	Imaging Vascularity in Primary Breast Cancer with Novel MRI Techniques
BRAID	Breast Screening - Risk Adaptive Imaging for Density - Full Text View - ClinicalTrials.gov
Compulse	Comparison Trial of Open-tip Pulsed Needle Biopsy and Conventional Core Biopsy in Axillary Lymph Nodes (COMPULSE)
EMBED1&2	Early Markers for Breast Cancer Detection (cam.ac.uk)
EMBRACE	EMBRACE Study - Centre for Cancer Genetic Epidemiology (cam.ac.uk)
HER2Radical	HER2-RADiCAL study (Response ADaptive CAre pLan) - tailoring treatment for HER2-positive (HER2+) early breast cancer. Patients with HER2+ early breast cancer who have recently completed standard of care (SoC) non-anthracycline-containing neoadjuvant systemic anti-cancer therapy (neoSACT) with pathological complete response (pCR; ypT0/Tis ypN0 M0).
IMpALA	A Proof of Concept, Window Trial of the IMmunological Effects of AveLumab and Aspirin in Triple-Negative Breast Cancer (IMpALA)
NeoRT	Neo-RT: A Study Investigating Whether Changing the Sequence of Treatments (Starting Radiotherapy Followed by Hormone Therapy Before Surgery) is Feasible - Full Text View - ClinicalTrials.gov
Loris	LORIS - University of Birmingham A Phase III Trial of Surgery versus Active Monitoring for Low Risk Ductal Carcinoma in Situ (DCIS) (CLOSED March 2020; no follow up)
MIAMI	MIAMI Safe Surgery for Multiple Breast Cancers - Full Text View - ClinicalTrials.gov
MyPeBs	My Personalized Breast Screening - Full Text View - ClinicalTrials.gov
NARNIA	Sodium (23Na) MRI for Tumour Characterisation and Assessment of Therapy Response in Breast Cancer - Full Text View - ClinicalTrials.gov
Optima	OPTIMA (optimabreaststudy.com) Optimal Personalised Treatment of early breast cancer using Multi-parameter Analysis

PARABLE	<u>Proton beam therapy in patients with breast cancer: evaluating early and late effects</u>
Partner / Partnering	<u>Platinum and Polyadenosine 5'Diphosphoribose Polymerisation (PARP) Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer (TNBC) and/or Germline BRCA (gBRCA) Positive Breast Cancer - Full Text View - ClinicalTrials.gov</u>
PBCP	Personalised Breast Cancer Program
Pioneer	<u>A Pre-operative Window Study of Letrozole Plus PR Agonist (Megestrol Acetate) Versus Letrozole Alone in Post-menopausal Patients With ER-positive Breast Cancer - Full Text View - ClinicalTrials.gov</u> COMPLETED NOV 2022
POSNOG	<u>POSNOG - A Trial Looking at Axillary Treatment in Early Breast Cancer - Full Text View - ClinicalTrials.gov</u>
Primetime	PRIMETIME - The Institute of Cancer Research, London (icr.ac.uk) Post-operative avoidance of radiotherapy: biomarker selection of women categorised to be in a very low risk group by IHC4+C.
Small	<u>The SMALL study for treating early-stage breast cancer NCRI</u>
TROPION-Breast03	<u>A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03) - Full Text View - ClinicalTrials.gov</u>

Advanced & Metastatic Breast Cancer Portfolio

Breast Ca type	Locally Advanced	Metastatic 1 st line	Metastatic 2 nd line	Metastatic 3 rd line +
Tumour DNA Seq + Molecular Therapy (Basket of Baskets)			<div>Anti-PDL-1 Atezolizumab</div> <div>[FGFR Inhibitor]</div> <div>[MET Inhibitor]</div>	
ER+ Her2-	<div>FAIM</div>	<div>Serena 4 – oral SERD</div> <div>Serena 6 – oral SERD</div> <div>FAIM</div>	<div>Serena 1 - Oral SERD</div> <div>[Poseidon 2 – Lobular]</div>	
Her2 Low			<div>Destiny Breast -06 – in follow up</div>	
Her2			<div>Destiny Breast -07</div>	
TNBC		<div>Begonia</div> <div>Petra</div>	<div>[Novel Immunotherapy: ICOS Inhibitor KY1044]</div>	
New Drug + radiotherapy				
Any	<div>KORTUC</div>			<div>PBCP</div> <div>DETECT (recruitment on hold)</div>

[Trials in set up]

Advanced Br Ca Trial information and links

Trial	Description
Begonia	A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer - Full Text View - ClinicalTrials.gov
BoB	A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets) - Full Text View - ClinicalTrials.gov
Calibrate	Cambridge Liquid Biopsy and Tumour Profiling Study for Patients on Experimental Therapeutics Trials - Full Text View - ClinicalTrials.gov
Destiny06	Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer - Full Text View - ClinicalTrials.gov
Destiny07	A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer - Full Text View - ClinicalTrials.gov
DETECT	A study looking at cancer cells and a substance called nucleic acid in the bloodstreams of women with breast cancer that has spread to other parts of the body (Detect) Cancer Research UK
Her2Climb02	A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer - Full Text View - ClinicalTrials.gov
[FAIM]	Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression - Full Text View - ClinicalTrials.gov
KORTUC	KORTUC Phase II - Intra-tumoural Radiation Sensitizer in Patients With Locally Advanced/Recurrent Breast Cancer - Full Text View - ClinicalTrials.gov
[KY1044]	Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer - Full Text View - ClinicalTrials.gov
Patriot	Phase I Study to Assess Safety of AZD6738 Alone and in Combination With Radiotherapy in Patients With Solid Tumours - Full Text View - ClinicalTrials.gov
PBCP	Personalised Breast Cancer Program
[PETRA]	Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies - Full Text View - ClinicalTrials.gov
Serena1	Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer - Full Text View - ClinicalTrials.gov
Serena4	A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease. - Full Text View - ClinicalTrials.gov
Serena6	Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6) - Full Text View - ClinicalTrials.gov